Sensus Healthcare (NASDAQ:SRTS) Releases Quarterly Earnings Results, Misses Expectations By $0.41 EPS

Key Points

• Sensus Healthcare reported a significant quarterly miss: EPS was a loss of $0.53, versus the expected loss of $0.12, while revenue of $2.29 million came in well below the $4.60 million estimate. The company posted a negative net margin of 34.50%.
• The stock remains under pressure but rose slightly: Shares traded at $3.16, near the lower end of their 52-week range of $2.66 to $5.49. The company has a market capitalization of approximately $52 million.
• Analyst sentiment is mixed: The consensus rating is “Hold,” with a target price of $6.75, although Wall Street Zen downgraded the stock to “strong sell” and Weiss Ratings maintained a sell rating. Institutional investors own about 25.3% of the company.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.41), FiscalAI reports. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $4.60 million. Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%.

Sensus Healthcare Stock Performance

NASDAQ:SRTS traded up $0.03 during trading hours on Thursday, hitting $3.16. 57,669 shares of the company's stock traded hands, compared to its average volume of 65,921. The firm has a market cap of $52.01 million, a P/E ratio of -6.72 and a beta of 1.10. Sensus Healthcare has a twelve month low of $2.66 and a twelve month high of $5.49. The stock's fifty day moving average price is $2.94 and its two-hundred day moving average price is $3.67.

Analysts Set New Price Targets

A number of analysts have commented on SRTS shares. Wall Street Zen lowered shares of Sensus Healthcare from a "sell" rating to a "strong sell" rating in a research note on Saturday, May 9th. Weiss Ratings restated a "sell (d)" rating on shares of Sensus Healthcare in a report on Friday, July 17th. Finally, Citigroup restated a "buy" rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $6.75.

Hedge Funds Weigh In On Sensus Healthcare

Institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare in the 4th quarter valued at about $77,000. Rothschild Wealth LLC acquired a new stake in shares of Sensus Healthcare during the fourth quarter worth approximately $500,000. Greenline Wealth Management LLC purchased a new position in Sensus Healthcare during the fourth quarter valued at approximately $513,000. Ingalls & Snyder LLC purchased a new position in Sensus Healthcare during the fourth quarter valued at approximately $219,000. Finally, State Street Corp increased its stake in Sensus Healthcare by 5.2% in the 4th quarter. State Street Corp now owns 69,252 shares of the company's stock valued at $276,000 after buying an additional 3,400 shares during the period. Hedge funds and other institutional investors own 25.30% of the company's stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source